Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJMSCs in Amyotrophic Lateral Sclerosis (ALS)
NCT04651855Phase 2Unknown
- Sponsor
- Polish Stem Cell Bank
- Start
- Dec 2020
- Primary completion
- Mar 2022
- Countries
- 1
01
Overview
Phase 2, open-label trial of wharton's jelly mesenchymal stromal cells in amyotrophic lateral sclerosis (ALS), sponsored by Polish Stem Cell Bank. Primary endpoint: Number of Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest at 18 months. Status: unknown.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04651855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04651855.